Post‑Surgical Tumor Handling: Pathology, Staging, Biobanking, and Disposal

After surgical resection, tumors follow a standardized pathway ensuring accurate diagnosis, staging, research contribution, and safe disposal.

1. Pathological Examination (Core)

  • Gross examination: Size, weight, margins, invasion, nodal dissection.
  • Histopathology (H&E): Tumor type, grade, margins, lymphovascular/perineural invasion, lymph node status.
  • Immunohistochemistry (IHC): Lineage markers, hormone receptors (ER/PR), HER2, mismatch repair, PD‑L1, etc.
  • Molecular / genomic testing: NGS panels, FISH, PCR for actionable mutations (EGFR, KRAS, BRAF, etc.), MSI, TMB.

2. Cancer Staging (AJCC TNM)

Integrates pathologic T (tumor), N (nodes), M (metastasis) with grade/biomarkers → stage group → guides adjuvant therapy decisions.

3. Biobanking / Research Use (With Informed Consent)

  • Fresh‑frozen tissue, FFPE blocks, blood (germline DNA, ctDNA), ascites/pleural fluid.
  • Stored in institutional biorepositories or cooperative groups (NCI CHTN, CPTAC).
  • Enables biomarker discovery, drug development, AI pathology training.
  • Governed by IRB, HIPAA, GINA; de‑identified or coded.

4. Disposal of Non‑Research Remnants

  • After retention period (typically 10+ years for blocks, 20+ for slides per CAP), remaining tissue is incinerated as regulated medical waste (RMW) per state/federal rules (RCRA, OSHA).
  • Documentation: chain‑of‑custody, destruction certificates.

5. Safety Throughout

  • Universal precautions, biosafety level 2 for fresh tissue.
  • Formalin/formalin‑fixed handling: ventilation, PPE, spill kits.

6. Patient Follow‑Up

  • Multidisciplinary tumor board review.
  • Surveillance imaging/labs per NCCN guidelines.
  • Survivorship care plan.

This systematic approach maximizes diagnostic accuracy, therapeutic precision, and scientific progress.

Tumors - Related Articles